Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 4/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14401638 | 0.92 | PTGDR2 (0.40) | PTGDR2ALDH1A1ATAD2HSPA9BACE1 | |
| SCHEMBL13233720 | 0.82 | F2RL3 (0.41) | MDM2PTGDR2ALDH1A1LMNAHSPA9 | |
| SCHEMBL14401726 | 0.82 | BACE1 (0.38) | PTGDR2ALDH1A1ATAD2BACE1 | |
| SCHEMBL5007556 | 0.79 | HSPA9 (0.39) | ATAD2LMNAHSPA9 | |
| SCHEMBL13233745 | 0.77 | PTGDR2 (0.39) | PTGDR2ALDH1A1ATAD2BACE1 | |
| SCHEMBL2488947 | 0.77 | TDP1 (0.50) | MDM2ALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL1368159 | 0.77 | ATAD2 (0.48) | ALDH1A1ATAD2LMNASMN1; SMN2HSPA9 | |
| SCHEMBL4130724 | 0.76 | ALDH1A1 (0.36) | PTGDR2ALDH1A1BACE1POLB | |
| SCHEMBL5007572 | 0.74 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL31251184 | 0.73 | CYP3A4 (0.42) | ATAD2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7749994-B2 | Pentacyclic kinase inhibitors | GENENTECH, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7749994-B2 | Pentacyclic kinase inhibitors | GENENTECH, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20080318989-A1 | Pyrimidine Kinase Inhibitors | GENENTECH, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080318989-A1 | Pyrimidine Kinase Inhibitors | GENENTECH, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080318989-A1 | Pyrimidine Kinase Inhibitors | GENENTECH, INC. | 2008-12-25 | — | — | US | disclosed |
| EP-1968950-A1 | PYRIMIDINE KINASE INHIBITORS | Genentech, Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007120339-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120339-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007022102-A2 | PENTACYCLIC KINASE INHIBITORS | GENENTECH, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037791-A1 | serine/threonine kinase inhibitors, useful for therapy and/or prophylaxis of cancers in mammals | HOFFMAN-LAROUCHE, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037791-A1 | serine/threonine kinase inhibitors, useful for therapy and/or prophylaxis of cancers in mammals | HOFFMAN-LAROUCHE, INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318989-A1 | Pyrimidine Kinase Inhibitors | DCK, DTYMK, TK1 | MDM2 1238/4885PTGDR2 3146/4885ALDH1A1 2990/4885 |
| US-20070037791-A1 | serine/threonine kinase inhibitors, useful for therapy and/or prophylaxis of cancers in mammals | RAF1, CHEK1, BRAF | MDM2 459/4885PTGDR2 2908/4885ALDH1A1 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.